[2] [2] ADASHI E Y, O'MAHONY D P, GLENN COHEN I. The FDA modernization act 2.0: drug testing in animals is rendered optional[J]. Am J Med, 2023, 136(9): 853-854. DOI: 10.1016/j.amjmed.2023.03.033.

[3] [3] U.S. FOOD & DRUG. FDA announces plan to phase out animal testing requirement for monoclonal antibodies and other drugs[EB/OL]. (2025-04-10) [2025-07-10]. https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs.

[4] [4] AKASH S R, ARNOB M A J B, UDDIN M J. FDA Modernization Act 2.0: An insight from nondeveloping country[J]. Drug Dev Res, 2023, 84(8): 1572-1577. DOI: 10.1002/ddr.22108.

[5] [5] AVEY M T, FENWICK N, GRIFFIN G. The use of systematic reviews and reporting guidelines to advance the implementation of the 3Rs[J]. J Am Assoc Lab Anim Sci, 2015, 54(2): 153-162.

[6] [6] CENCI M A, WHISHAW I Q, SCHALLERT T. Models for human neurological disease: both rats and primates are needed[J]. Nat Rev Neurosci, 2002, 3(7): 580. DOI: 10.1038/nrn877-c2.

[7] [7] THACKRAY A M, ANDROLETTI O, BUJDOSO R. The use of PrP transgenicDrosophilato replace and reduce vertebrate hosts in the bioassay of mammalian prion infectivity[J]. F1000Res, 2018, 7: 595. DOI: 10.12688/f1000research.14753.1.

[8] [8] KOJIMA H. History of the Organisation for Economic co-operation and Development (OECD) test guidelines for non-animal test methods in Japan[J]. Genes Environ, 2025, 47(1): 3. DOI: 10.1186/s41021-024-00323-7.

[9] [9] JEONG D H, JUNG D W, LEE H S. Confirmation of the steroid hormone receptor-mediated endocrine disrupting potential of fenvalerate following the Organization for Economic Cooperation and Development test guidelines, and its estrogen receptor -dependent effects on lipid accumulation[J]. Comp Biochem Physiol C Toxicol Pharmacol, 2024, 283: 109955. DOI: 10.1016/j.cbpc.2024.109955.

[10] [10] KNETZGER N, ERTYCH N, BURGDORF T, et al. Non-invasivein vitroNAM for the detection of reversible and irreversible eye damage after chemical exposure for GHS classification purposes (ImAi)[J]. Arch Toxicol, 2025, 99(3): 1011-1028. DOI: 10.1007/s00204-024-03940-x.

[11] [11] FRANK GERBERICK G. The use of peptide reactivity assays for skin sensitisation hazard identification and risk assessment[J]. Altern Lab Anim, 2016, 44(5): 437-442. DOI: 10.1177/026119291604400506.

[12] [12] KOLESNYK S, BUBALO N, PRODANCHUK M, et al. Differences in classification for skin corrosion/irritation in EU and Ukraine: Case study of alternative (in vitro and in silico) methods application for classification of pesticide active ingredient imazamox[J]. Toxicol Vitro, 2019, 60: 71-75. DOI: 10.1016/j.tiv.2019.05.007.

[13] [13] MORALES M, PREZ D, CORREA L, et al. Evaluation of fibrin-based dermal-epidermal organotypic cultures forin vitroskin corrosion and irritation testing of chemicals according to OECD TG 431 and 439[J]. Toxicol Vitro, 2016, 36: 89-96. DOI: 10.1016/j.tiv.2016.07.010.

[14] [14] SUZUKI H, SAKABE T, HIROSE Y, et al. Development and evaluation of yeast-based GFP and luciferase reporter assays for chemical-induced genotoxicity and oxidative damage[J]. Appl Microbiol Biotechnol, 2017, 101(2): 659-671. DOI: 10.1007/s00253-016-7911-z.